Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
Key Highlights
- ➤New lorundrostat data to be presented at ASN Kidney Week 2026 October 21-25
- ➤Presentation covers blood pressure and albuminuria reduction in CKD stages 1 to 3
- ➤Launch-HTN was a global randomized placebo-controlled Phase 3 trial
- ➤Trial enrolled adults with uncontrolled blood pressure despite two to five medications
Expert Statements
Liffert Vogt, Professor of Nephrology and Renal Transplantation at Amsterdam University Medical Center and University of Amsterdam
“Blood Pressure and Albuminuria Reduction with Lorundrostat in Chronic Kidney Disease Stages 1 to 3 in the Launch-HTN trial”
RADNOR, Pa., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that new data from the Launch-HTN trial of lorundrostat will be presented at the American Society of Nephrology Kidney Week 2026, taking place October 21-25 in Denver, Colorado.
Title:Blood Pressure and Albuminuria Reduction with Lorundrostat in Chronic Kidney Disease Stages 1 to 3 in the Launch-HTN trial
Get started
Create a free account to read the full story.